FY2025 EPS Estimates for Adicet Bio Cut by HC Wainwright

Adicet Bio, Inc. (NASDAQ:ACET) – Equities researchers at HC Wainwright decreased their FY2025 EPS estimates for Adicet Bio in a research report issued to clients and investors on Wednesday, January 21st. HC Wainwright analyst R. Burns now expects that the company will earn ($18.36) per share for the year, down from their previous estimate of ($18.08). HC Wainwright has a “Buy” rating and a $50.00 price target on the stock. The consensus estimate for Adicet Bio’s current full-year earnings is ($1.39) per share. HC Wainwright also issued estimates for Adicet Bio’s Q4 2025 earnings at ($3.59) EPS, Q1 2026 earnings at ($2.91) EPS, Q2 2026 earnings at ($3.00) EPS, Q3 2026 earnings at ($3.08) EPS, Q4 2026 earnings at ($3.17) EPS and FY2026 earnings at ($12.17) EPS.

Other equities analysts have also recently issued reports about the stock. Citigroup reissued a “market perform” rating on shares of Adicet Bio in a research note on Wednesday, November 19th. Guggenheim increased their price target on shares of Adicet Bio from $112.00 to $128.00 and gave the company a “buy” rating in a research note on Wednesday, October 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Adicet Bio in a research note on Thursday, October 30th. Jefferies Financial Group raised shares of Adicet Bio to a “strong-buy” rating in a report on Tuesday, October 7th. Finally, Canaccord Genuity Group set a $18.00 target price on shares of Adicet Bio and gave the company a “buy” rating in a research note on Tuesday, January 6th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $69.00.

Adicet Bio Stock Performance

Shares of NASDAQ ACET opened at $8.44 on Friday. Adicet Bio has a 52 week low of $7.15 and a 52 week high of $17.44. The stock has a market capitalization of $80.86 million, a PE ratio of -0.42 and a beta of 1.60. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.62 and a current ratio of 5.62. The stock has a 50 day moving average price of $8.51 and a 200 day moving average price of $11.05.

Adicet Bio (NASDAQ:ACET) last posted its quarterly earnings data on Wednesday, November 5th. The company reported ($4.64) EPS for the quarter, missing analysts’ consensus estimates of ($4.16) by ($0.48).

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Susquehanna International Group LLP bought a new position in Adicet Bio in the 3rd quarter valued at about $33,000. Squarepoint Ops LLC bought a new position in shares of Adicet Bio during the third quarter worth approximately $38,000. Vontobel Holding Ltd. increased its stake in shares of Adicet Bio by 33.3% during the second quarter. Vontobel Holding Ltd. now owns 80,000 shares of the company’s stock worth $49,000 after purchasing an additional 20,000 shares during the period. FNY Investment Advisers LLC acquired a new stake in Adicet Bio during the 4th quarter worth approximately $51,000. Finally, Virtu Financial LLC bought a new stake in Adicet Bio in the 3rd quarter valued at $65,000. Institutional investors and hedge funds own 83.89% of the company’s stock.

About Adicet Bio

Adicet Bio, Inc (NASDAQ: ACET) is a clinical‐stage biotechnology company specializing in the development of off‐the‐shelf, allogeneic gamma delta (γδ) T cell therapies for oncology and autoimmune disorders. The company’s proprietary platform enables the genetic engineering of γδ T cells with chimeric antigen receptors (CARs) and other molecular modifications to enhance tumor targeting, expansion, and persistence. By leveraging the innate tumor-recognition properties of γδ T cells, Adicet seeks to overcome the manufacturing and safety challenges associated with autologous cell therapies.

Adicet’s lead product candidate, ADI-001, is a CAR‐engineered allogeneic γδ T cell therapy directed against CD20 for the treatment of relapsed or refractory B-cell malignancies.